Morris Susan J, Sebastian Sarah, Spencer Alexandra J, Gilbert Sarah C
Jenner Institute, ORCRB, University of Oxford, Off Roosevelt Drive, Headington, Oxford, OX3 7DQ, UK.
Future Virol. 2016 Sep;11(9):649-659. doi: 10.2217/fvl-2016-0070. Epub 2016 Sep 15.
Replication incompetent human adenovirus serotype 5 (HAdV-C5) has been extensively used as a delivery vehicle for gene therapy proteins and infectious disease antigens. These vectors infect replicating and nonreplicating cells, have a broad tissue tropism, elicit high immune responses and are easily purified to high titers. However, the utility of HAdV-C5 vectors as potential vaccines is limited due to pre-existing immunity within the human population that significantly reduces the immunogenicity of HAdV-C5 vaccines. In recent years, adenovirus vaccine development has focused on simian-derived adenoviral vectors, which have the desirable vector characteristics of HAdV-C5 but with negligible seroprevalence in the human population. Here, we discuss recent advances in simian adenovirus vaccine vector development and evaluate current research specifically focusing on clinical trial data.
复制缺陷型人5型腺病毒（HAdV-C5）已被广泛用作基因治疗蛋白和传染病抗原的递送载体。这些载体可感染正在复制和非复制的细胞，具有广泛的组织嗜性，引发强烈的免疫反应，并且易于纯化至高滴度。然而，由于人群中预先存在的免疫力会显著降低HAdV-C5疫苗的免疫原性，HAdV-C5载体作为潜在疫苗的效用受到限制。近年来，腺病毒疫苗的开发主要集中在猿猴来源的腺病毒载体上，这些载体具有HAdV-C5理想的载体特性，但在人群中的血清阳性率可忽略不计。在此，我们讨论猿猴腺病毒疫苗载体开发的最新进展，并特别针对临床试验数据评估当前的研究情况。
